NCT06919393Recruiting
"Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL
"Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia: Molecular Characterization, Identification and New Stratification
Source: ClinicalTrials.gov · Last updated 9 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
It is a multicenter, non-interventional, non pharmacological, translational, prospective study. Any decision about drug administration is made by the physician based on his clinical judgment in the context of clinical practice, independently from the decision to include the patient in the study.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 25 Feb 2021
- Start date
- 23 Oct 2019
- Primary completion date
- Jan 2026
- Lead sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Diseases
- Acute lymphoblastic leukaemia
- NCT number
- NCT06919393
What you commit to
- Study type: Observational
- Planned participants: 60
- From 23 Oct 2019 to the primary completion date, Jan 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \< 18 years;
Other
- B-ALL positive for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements.
- Low blast percentage (\<70%) samples could be excluded for molecular evaluations, not for cytofluorimetric analyses;
Who the study is looking for
- Participant is willing and able to give informed consent for participation in the study;
- Patients with new diagnosis and/or relapse/s of primary or secondary B-ALL;
- Negative for BCR-ABL1 t(9;22); TCF3-PBX1 t(1;19); MLL-AF4 t(4;11) rearrangements;
- Participant is willing and able to give informed consent for participation in the study;
- Male or Female, aged \>18 years;
- Availability of clinical data.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Irst-Irccs Coordinator of this site? Confirm its status | Meldola | Italy | Recruiting |
| Ospedale S. Maria delle Croci RAVENNA Coordinator of this site? Confirm its status | Ravenna | Italy | Recruiting |
| Ospedale "Infermi" Coordinator of this site? Confirm its status | Rimini | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.